A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

PURPOSE: This open-label, single-arm, phase II study evaluated the vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) rivoceranib in patients with recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC). PATIENTS AND METHODS: Eligible patients had confirmed d...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Glenn J., Ahn, Myung-Ju, Muzaffar, Jameel, Keam, Bhumsuk, Bowles, Daniel W., Wong, Deborah J., Ho, Alan L., Kim, Sung-Bae, Worden, Francis, Yun, Tak, Meng, Xianzhang, Van Tornout, Jan M., Conlan, Maureen G., Kang, Hyunseok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643996/
https://www.ncbi.nlm.nih.gov/pubmed/37643133
http://dx.doi.org/10.1158/1078-0432.CCR-23-1030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643996/
https://www.ncbi.nlm.nih.gov/pubmed/37643133
http://dx.doi.org/10.1158/1078-0432.CCR-23-1030

Ejemplares similares